Damora Therapeutics, Inc. (DMRA)
NASDAQ: DMRA · Real-Time Price · USD
26.52
-2.17 (-7.56%)
Mar 10, 2026, 1:34 PM EDT - Market open
Company Description
Damora Therapeutics, Inc., a clinical-stage biotechnology company, develops molecule therapeutics for the treatment of fibrosis, cancer, inflammation, and other related diseases.
It develops GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 and GB1211, an oral small molecule inhibitor of galectin-3 to treat multiple types of oncology and liver disease indications.
The company was founded in 2011 and is headquartered in Copenhagen, Denmark.
Damora Therapeutics, Inc.
| Country | Denmark |
| Founded | 2011 |
| Employees | 5 |
| CEO | Sherwin Sattarzadeh |
Contact Details
Address: Ole Maaloes Vej 3, Copenhagen N Copenhagen, 2200 Denmark | |
| Phone | 45 70 70 52 10 |
| Website | galecto.com |
Stock Details
| Ticker Symbol | DMRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
Key Executives
| Name | Position |
|---|---|
| Sherwin Sattarzadeh | Chief Executive Officer |
| Lori Firmani | Chief Financial Officer |
| Sherwin Sattarzadeh | Chief Operating Officer |